An experiment to determine the active therapeutic moiety of sulphasalazine.
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisAminosalicylates for induction of remission or response in Crohn's diseaseTraditional corticosteroids for induction of remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisPharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugsAminosalicylates for induction of remission or response in Crohn's diseaseMesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Inflammation and proliferation act together to mediate intestinal cell fusionNew steroids and new salicylates in inflammatory bowel disease: a critical appraisalOlsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre studyIntestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsInhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa BMesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis.Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity.Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats.Sulphasalazine and regression of rheumatoid nodulesIndications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?5-Aminosalicylic Acid Inhibits Acute Clostridium difficile Toxin A-Induced Colitis in Rats.5-ASA Dose-Response: Maximizing Efficacy and Adherence.Medical treatment of inflammatory bowel disease: new therapies, new drugs.Bacteria as the cause of ulcerative colitis.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.A budesonide prodrug accelerates treatment of colitis in rats.Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretionOptimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel diseaseInhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis.Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.Drug therapy of ulcerative colitisComparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.
P2860
Q24185774-C76F3188-D9AF-4B71-A02E-CB3660F33509Q24185876-5D6FA3A3-9F14-43E3-9D44-26606B5E53BCQ24198024-D5BD7E5C-1FFB-4162-A30F-EDB758F30297Q24198786-86ECC24B-8A79-4983-A841-60526E685C26Q24235730-6511F6FF-F561-449C-BED5-EFC27CBB7258Q24242955-BDA52F52-1D22-4B7E-BBDD-C53DE152498BQ24245127-E6538A1E-1BB1-4FE2-B2CB-BCF1D6C13F2DQ24246085-0A75B9D5-12EE-4531-A771-40D113ED6D2FQ24246220-CFADE618-544E-4DF9-B0DA-34971EB7DD5EQ24672983-512BFBFF-B894-49AA-8E68-68F950944E4BQ26471183-97FDA7D1-EB84-415E-8BA3-C8E286378947Q26777634-E98C0174-5460-4C05-9973-80751DCD0626Q27345379-98B74C3B-7955-4B68-90F3-14AC42FBE5FEQ28192793-9C445D45-E975-435C-921D-D6E747205185Q28353977-1B30BE39-F2F4-4D08-B9FD-092A0CA576C3Q28360107-2B7AF698-CD51-454E-BD07-FCE69B741E33Q28369487-11AC63D6-0481-4D34-89AB-FC2105C2183FQ28379350-56D7D72D-4B54-49D8-BDB8-63FB25CEBC92Q30638019-1D164415-C737-49B4-8042-447D195A38F2Q33287467-E2B8FF4A-639B-4448-81DC-50CCD661949AQ33406895-EE4730D5-9997-4866-B479-907D134090E8Q33509847-0DFA114A-667E-4561-A6D5-65A00C7EE875Q33515113-F1CC141C-45EF-44D5-B420-0AE77363EF41Q33557331-9478EB21-BD6F-4B20-A4C9-321C1573B462Q33868970-C7CCF3C8-F2A0-4A4E-B1BE-BA199412BD4AQ33876268-21C9BBE4-230B-4710-8C17-45E0672C6123Q33916329-C0FDE339-E8E4-4114-9F7C-A2671795B442Q34100485-EEC1557F-DCF2-4C46-8ADF-1F33D1062C0FQ34104389-16B73886-BE07-4EA4-8183-D760092B25D6Q34273329-B9EBC82E-CC03-46C8-AD01-2DA0A86BF13AQ34379809-7A191BED-1534-4C28-A531-638240905D45Q34393049-A994BA63-728D-4B7D-A3B1-B43C3A8D0755Q34394096-7EB2A3A2-DA85-40F1-B94E-A41D80E4F0ABQ34394984-E6CC6057-8624-4324-B9ED-665F124D3B7EQ34395621-35D4F23F-6D84-42D5-8C79-CF735FFA9941Q34395764-7FF7DB65-6557-4ABD-91A7-F7BE27089918Q34396521-76CD1A86-E4A8-4607-A19D-39E5EDCCD22FQ34403155-F416EE8A-926A-4BBE-83C0-2225918A1A0DQ34403704-DCE86CF2-42F3-4428-9083-95C407A74D08Q34416779-40DFC786-C451-4C56-9F53-66157188277B
P2860
An experiment to determine the active therapeutic moiety of sulphasalazine.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
An experiment to determine the active therapeutic moiety of sulphasalazine.
@en
An experiment to determine the active therapeutic moiety of sulphasalazine.
@nl
type
label
An experiment to determine the active therapeutic moiety of sulphasalazine.
@en
An experiment to determine the active therapeutic moiety of sulphasalazine.
@nl
prefLabel
An experiment to determine the active therapeutic moiety of sulphasalazine.
@en
An experiment to determine the active therapeutic moiety of sulphasalazine.
@nl
P2093
P1433
P1476
An experiment to determine the active therapeutic moiety of sulphasalazine.
@en
P2093
A K Azad Khan
S C Truelove
P304
P356
10.1016/S0140-6736(77)90831-5
P407
P577
1977-10-01T00:00:00Z